TREATMENT IMPLICATIONS OF THE REDUCE-IT RESULTS TO PEOPLE OF SOUTH ASIAN (SA) DESCENT LIVING IN CANADA WITH KNOWN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE(THE REDUCE-IT CANADA SA STUDY)

Abstract

The REDUCE-IT trial demonstrated that icosapent ethyl (IPE), a highly purified eicosapentaenoic acid ethyl ester, lowers cardiovascular (CV) events and CV death in statin-treated individuals with mild-moderate hypertriglyceridemia, relatively well-controlled low-density lipoprotein cholesterol (LDL-C) levels and with either known CV disease or diabetes with other risk factors. Inasmuch as over 90% of the REDUCE-IT cohort were White, the generalization of its results to non-White populations is unclear.